To buy or not to buy, that’s the question. For even the most seasoned Wall Street observers, determining the ideal time to pull …
Earlier this week, DURECT Corporation (NASDAQ:DRRX) announced an exclusive U.S.
DURECT Corporation (NASDAQ:DRRX) investors cheer the news that the company has achieved positive biomarker readout from DUR-928 Phase 1b trial in nonalcoholic steatohepatitis …
Yesterday, DURECT Corporation’s (NASDAQ:DRRX) licensee Pain Therapeutics announced that it had received a complete response letter (CRL) from the FDA for the resubmitted …
DURECT Corporation (NASDAQ:DRRX) is watching its shares tank nearly 30% in Monday’s session after receiving a Complete Response Letter from the U.S.
On August 1st, biotech firm DURECT Corporation (NASDAQ:DRRX) released its second quarter financial results for this year. In reaction, Rodman & Renshaw analyst …
DURECT Corporation (NASDAQ:DRRX) announced financial results for the second quarter of 2016. Total revenues were $3.
Healthcare analysts weighed in on shares of DURECT Corporation (NASDAQ:DRRX) after the biotech reported its 2016 first quarter financial results last week. At this …
DURECT Corporation (NASDAQ:DRRX) announced that it is offering, subject to market conditions, shares of its common stock in an underwritten public offering. DURECT anticipates …
In a research report released Tuesday, Cantor analyst Irina Rivkind initiated coverage on shares of DURECT Corporation (NASDAQ:DRRX) with a Hold rating and a price …
